stoxline Quote Chart Rank Option Currency Glossary
Aspira Women's Health Inc. (AWH)
3.49  0 (0%)    04-19 16:00
Open: 3.56
High: 3.56
Volume: 6,952
Pre. Close: 3.49
Low: 3.42
Market Cap: 43(M)
Technical analysis
2024-04-19 5:07:55 PM
Short term     
Mid term     
Targets 6-month :  4.45 1-year :  5.19
Resists First :  3.8 Second :  4.45
Pivot price 3.13
Supports First :  3 Second :  2.5
MAs MA(5) :  3.47 MA(20) :  3.21
MA(100) :  3.87 MA(250) :  3.94
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  86.1 D(3) :  82.7
RSI RSI(14): 53
52-week High :  6.75 Low :  2.3
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ AWH ] has closed below upper band by 22.1%. Bollinger Bands are 9.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.56 - 3.58 3.58 - 3.59
Low: 3.38 - 3.4 3.4 - 3.41
Close: 3.46 - 3.49 3.49 - 3.52
Company Description

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.

Headline News

Tue, 02 Apr 2024
Aspira Women's Health (NASDAQ:AWH) Price Target Lowered to $3.30 at Cantor Fitzgerald - Defense World

Thu, 28 Mar 2024
Aspira Women's Health Inc. (AWH) Q4 2023 Earnings Call Transcript - Seeking Alpha

Thu, 29 Feb 2024
Aspira Women's Health Insiders Up US$196k On US$702.9k Investment - Simply Wall St

Wed, 21 Feb 2024
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health - Benzinga

Mon, 12 Feb 2024
AWH Stock Quote Price and Forecast - CNN

Fri, 16 Jun 2023
Latest CFO Moves - June 16, 2023 - Boardroom Alpha - TheStreet

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical - Diagnostics & Research
Shares Out 12 (M)
Shares Float 9 (M)
Held by Insiders 38.8 (%)
Held by Institutions 9 (%)
Shares Short 134 (K)
Shares Short P.Month 170 (K)
Stock Financials
EPS -1.81
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.22
Profit Margin -182.4 %
Operating Margin -194.2 %
Return on Assets (ttm) -99.7 %
Return on Equity (ttm) -723.5 %
Qtrly Rev. Growth -1.2 %
Gross Profit (p.s.) 0
Sales Per Share 0.74
EBITDA (p.s.) -1.52
Qtrly Earnings Growth 0 %
Operating Cash Flow -16 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -1.93
PEG Ratio 0
Price to Book value -15.87
Price to Sales 4.7
Price to Cash Flow -2.72
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android